UBS has downgraded Jazz Pharmaceuticals PLC (JAZZ) to a Neutral rating from Buy, effective November 23, 2025. The current share price stands at $180.90.
This decision underscores growing caution regarding Jazz Pharmaceuticals' outlook. Analysts may be responding to competitive pressures, evolving market conditions, or execution risks that could affect the company's performance.
Jazz Pharmaceuticals, headquartered in Dublin, operates as a biopharmaceutical company focused on developing and commercializing products in narcolepsy, oncology, pain, and psychiatry. The firm boasts a diverse portfolio, including therapies for sleep disorders and cancer treatments. Its lead-marketed products feature Xywav, Epidiolex, and Zepzelca, among others. The company currently has a market capitalization of $10.8 billion and an earnings per share (EPS) of -6.07.
Upcoming earnings reports are anticipated on May 4, 2026, with an EPS estimate of $4.95 and revenue estimated at $996.6 million. This follows a strong Q3 2025 performance, where EPS reached $8.13, surpassing expectations by 34.7%.
Analyst ratings serve as professional insights based on extensive research and financial modeling. While these assessments can inform investor perspectives, they are based on assumptions that may not always materialize. Investors should consider a range of factors, including company fundamentals and industry trends, when making decisions. Analyst opinions can shift over time as new information becomes available, leading to varying views on the same company.